- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05907655
Sistema glinfatico nell'emicrania
Scoperta del ruolo funzionale del sistema glinfatico nella genesi dell'attacco di emicrania
This study aimed to investigate the role of the glymphatic system in the initiation of migraine attacks, using non-invasive magnetic resonance imaging techniques and a validated model of migraine induction by nitroglycerin administration. Secondarily, the relationship between the function of the glymphatic system during nitroglycerin-induced migraine attacks and sleep architecture and plasma levels of migraine-involved neuropeptides will be investigated.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Roberta Messina, MD, PhD
- Numero di telefono: 00390226433944
- Email: messina.roberta@hsr.it
Luoghi di studio
-
-
Milan
-
Milan, Milan, Italia, 20132
- Reclutamento
- IRCCS San Raffaele Hospital
-
Contatto:
- Roberta Messina, MD, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients with a diagnosis of episodic migraine without aura, by the standard ICHD diagnostic criteria, will be prospectively recruited. Patients will be allowed to take only one migraine preventive treatment at a stable dose during the study. Healthy controls suffering from any headaches with the exception of infrequent tension-type headache will be excluded from the study.
Descrizione
Inclusion Criteria:
For patients:
• Diagnosis of migraine, by the ICHD-3 criteria;
For both patients and healthy controls:
- Age between 18 and 60 years;
- Willing and able to comply with scheduled visits.
Exclusion criteria
For patients:
- Overuse of acute medications for headache;
- Continuous or daily headache;
- Other primary headache disorders, with the exception of infrequent tension-type headache.
For healthy controls:
• Any subject with frequent tension type headache, migraine, cluster headache, other pain syndromes or neurological conditions.
For both patients and healthy controls:
- Allergy to nitroglycerin;
- Major psychiatric disorders such as bipolar affective disorder and schizophrenia;
- Cardiovascular diseases that contraindicated the use of nitroglycerin;
- Intracranial hypertension;
- Cerebral haemorrhage;
- Cerebral trauma;
- Pulmonary toxic oedema;
- Closed angle glaucoma;
- Anaemia;
- Pregnancy and breastfeeding;
- Aortic stenosis or significant hypotension (SBP<90mmHg or <100mmHg and symptomatic) precluding nitroglycerin administration;
- Use of sildenafil;
- Any person unable to lie still within the environment of the MRI scanner for the required period to perform the study;
- Any person where MRI scanning is contraindicated (metal implants, pacemaker, claustrophobia, etc.);
- Use of illicit drugs;
- MRI head showing any brain pathology, such as space-occupying lesions;
- Any person unable to understand and follow the instructions of the investigators.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_CONTROL
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Adult patients with migraine
Diagnosis of migraine, by the ICHD-3 criteria. Age between 18 and 60 years. Female and males. Right-handed |
Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls. The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images. Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis. Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging. |
|
Healthy controls
Age between 18 and 60 years. Female and males. Right-handed |
Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls. The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images. Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis. Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline glymphatic function after nitroglycerin administration
Lasso di tempo: Up to 8 hours
|
The DTI-ALPS index will be quantified before and after nitroglycerin administration as an indirect measure of the glymphatic function |
Up to 8 hours
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline plasma levels of neuropeptides after nitroglycerin administration
Lasso di tempo: Up to 8 hours
|
ELISA kits will be used to measure the plasma level of neuropeptides involved in migraine pathophysiology before and after nitroglycerin administration |
Up to 8 hours
|
|
Change from baseline sleep architecture after nitroglycerin administration
Lasso di tempo: Up to 8 hours
|
Sleep Architecture will be studied through the Sleep Profiler before and after nitroglycerin administration |
Up to 8 hours
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Roberta Messina, MD, PhD, IRCCS San Raffaele Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Disturbi della cefalea, primaria
- Disturbi della cefalea
- Disturbi dell'emicrania
- Prodotti chimici organici
- Tecniche investigative
- Gestione dei campioni
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Forature
- Procedure chirurgiche, operative
- Composti nitro
- Nitroglicerina
- Collezione di campioni di sangue
Altri numeri di identificazione dello studio
- GR-2021-12374851
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .